Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells

Journal of Immunology

Volumn 181, Issue 7, 2008, Pages 4666-4675

  Sinha, Pratima ^a   Okoro, Chinonyerem ^a   Foell, Dirk ^b   Freeze, Hudson H ^c   Ostrand Rosenberg, Suzanne ^a   Srikrishna, Geetha ^c  

^a UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ARGINASE; B7 ANTIGEN; CALGRANULIN A; CALGRANULIN B; CD11B ANTIGEN; CELL SURFACE PROTEIN; ENZYME INHIBITOR; GLYCAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 4 RECEPTOR ALPHA; INTERLEUKIN 6; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY GB3.1; N(W) HYDROXY NORARGININE DIACETIC ACID; PROSTAGLANDIN E2; RECEPTOR PROTEIN; UNCLASSIFIED DRUG; AUTACOID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BLOOD; BONE MARROW; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CANCER SIZE; CANCER SURGERY; CARCINOGENESIS; CARCINOMA CELL; CELL ACTIVATION; CELL MIGRATION; CELL STIMULATION; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CHEMOTAXIS; CONTROLLED STUDY; DENDRITIC CELL; IMMUNOREGULATION; IN VIVO STUDY; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; LYMPHOID ORGAN; METASTASIS; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; SPLEEN; SUPPRESSOR CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR LOCALIZATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BONE MARROW CANCER; BONE MARROW CELL; CELL CULTURE; EXPERIMENTAL NEOPLASM; IMMUNOLOGY; IMMUNOPHENOTYPING; LUNG TUMOR; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PHYSIOLOGY; SECRETION; SPLEEN TUMOR; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; BONE MARROW NEOPLASMS; CALGRANULIN A; CALGRANULIN B; CELL LINE, TUMOR; CELLS, CULTURED; CHEMOTAXIS, LEUKOCYTE; IMMUNOPHENOTYPING; INFLAMMATION MEDIATORS; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MYELOID CELLS; SPLENIC NEOPLASMS;

EID: 53349125963     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.7.4666     Document Type: Article

References (65)

1. Balkwill, F., and A. Mantovani. 2001. Inflammation and cancer: back to Virchow? Lancet 357: 539-545. (Pubitemid 32173595)
2. Coussens, L. M., and Z. Werb. 2002. Inflammation and cancer. Nature 420: 860-867.
3. Ruegg, C. 2006. Leukocytes, inflammation, and angiogenesis in cancer: fatal attractions. J. Leukocyte Biol. 80: 682-684. (Pubitemid 44835881)
4. Luo, J. L., S. Maeda, L. C. Hsu, H. Yagita, and M. Karin. 2004. Inhibition of NF-κB in cancer cells converts inflammation- induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression. Cancer Cell. 6: 297-305.
5. Karin, M., and F. R. Greten. 2005. NF-κB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5: 749-759. (Pubitemid 41400849)
6. Gebhardt, C., A. Riehl, M. Durchdewald, J. Nemeth, G. Furstenberger, K. Muller-Decker, A. Enk, B. Arnold, A. Bierhaus, P. P. Nawroth, et al. 2008. RAGE signaling sustains inflammation and promotes tumor development. J. Exp. Med. 205: 275-285. (Pubitemid 351281593)
7. Lin, W. W., and M. Karin. 2007. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 117: 1175-1183. (Pubitemid 46718402)
8. Bunt, S. K., P. Sinha, V. K. Clements, J. Leips, and S. Ostrand-Rosenberg. 2006. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol. 176: 284-290.
9. Bunt, S. K., L. Yang, P. Sinha, V. K. Clements, J. Leips, and S. Ostrand-Rosenberg. 2007. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 67: 10019-10026.
10. 2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 67: 4507-4513.
11. + immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1β-secreting cells. J. Immunol. 175: 8200-8208.
12. Rodriguez, P. C., C. P. Hernandez, D. Quiceno, S. M. Dubinett, J. Zabaleta, J. B. Ochoa, J. Gilbert, and A. C. Ochoa. 2005. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J. Exp. Med. 202: 931-939. (Pubitemid 41396893)
13. Foell, D., H. Wittkowski, T. Vogl, and J. Roth. 2007. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J. Leukocyte Biol. 81: 28-37. (Pubitemid 46021248)
14. Donato, R. 2001. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int. J. Biochem. Cell. Biol. 33: 637-668. (Pubitemid 32520962)
15. Roth, J., T. Vogl, C. Sorg, and C. Sunderkotter. 2003. Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. Trends Immunol. 24: 155-158. (Pubitemid 36412096)
16. Foell, D., M. Frosch, C. Sorg, and J. Roth. 2004. Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation. Clin. Chim. Acta 344: 37-51. (Pubitemid 38626135)
17. Gebhardt, C., J. Nemeth, P. Angel, and J. Hess. 2006. S100A8 and S100A9 in inflammation and cancer. Biochem. Pharmacol. 72: 1622-1631.
18. Robinson, M. J., P. Tessier, R. Poulsom, and N. Hogg. 2002. The S100 family heterodimer, MRP-8/14, binds with high affinity to heparin and heparan sulfate glycosaminoglycans on endothelial cells. J. Biol. Chem. 277: 3658-3665.
19. Vogl, T., K. Tenbrock, S. Ludwig, N. Leukert, C. Ehrhardt, M. A. van Zoelen, W. Nacken, D. Foell, T. van der Poll, C. Sorg, and J. Roth. 2007. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin- induced shock. Nat. Med. 13: 1042-1049. (Pubitemid 47517513)
20. Srikrishna, G., K. Panneerselvam, V. Westphal, V. Abraham, A. Varki, and H. H. Freeze. 2001. Two proteins modulating transendothelial migration of leukocytes recognize novel carboxylated glycans on endothelial cells. J. Immunol. 166: 4678-4688. (Pubitemid 32233755)
21. Srikrishna, G., D. K. Toomre, A. Manzi, K. Panneerselvam, H. H. Freeze, A. Varki, and N. M. Varki. 2001. A novel anionic modification of N-glycans on mammalian endothelial cells is recognized by activated neutrophils and modulates acute inflammatory responses. J. Immunol. 166: 624-632. (Pubitemid 32038486)
22. Srikrishna, G., O. Turovskaya, R. Shaikh, R. Newlin, D. Foell, S. Murch, M. Kronenberg, and H. H. Freeze. 2005. Carboxylated glycans mediate colitis through activation of NF-κ B. J. Immunol. 175: 5412-5422. (Pubitemid 41456427)
23. Srikrishna, G., H. J. Huttunen, L. Johansson, B. Weigle, Y. Yamaguchi, H. Rauvala, and H. H. Freeze. 2002. N-Glycans on the receptor for advanced glycation end products influence amphoterin binding and neurite outgrowth. J. Neurochem. 80: 998-1008. (Pubitemid 34809952)
24. Hofmann, M. A., S. Drury, C. Fu, W. Qu, A. Taguchi, Y. Lu, C. Avila, N. Kambham, A. Bierhaus, P. Nawroth, et al. 1999. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97: 889-901.
25. Ghavami, S., I. Rashedi, B. M. Dattilo, M. Eshraghi, W. J. Chazin, M. Hashemi, S. Wesselborg, C. Kerkhoff, and M. Los. 2008. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J. Leukocyte Biol. 83: 1484-1492. (Pubitemid 351960330)
26. Boyd, J. H., B. Kan, H. Roberts, Y. Wang, and K. R. Walley. 2008. S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products. Circ. Res. 102: 1239-1246.
27. Turovskaya, O., D. Foell, P. Sinha, T. Vogl, R. Newlin, J. Nayak, M. Nguyen, P. Nawroth, A. Bierhaus, N. Varki, et al. 2008. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis associated carcinogenesis. Carcinogenesis epub ahead of print.
28. Sinha, P., V. K. Clements, and S. Ostrand-Rosenberg. 2005. Reduction of myeloid- derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J. Immunol. 174: 636-645. (Pubitemid 40094255)
29. Pulaski, B. A., and S. Ostrand-Rosenberg. 1998. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 58: 1486-1493.
30. Sinha, P., V. K. Clements, S. K. Bunt, S. M. Albelda, and S. Ostrand-Rosenberg. 2007. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 179: 977-983.
31. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-δ δ C(T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
32. Vandal, K., P. Rouleau, A. Boivin, C. Ryckman, M. Talbot, and P. A. Tessier. 2003. Blockade of S100A8 and S100A9 suppresses neutrophil migration in response to lipopolysaccharide. J. Immunol. 171: 2602-2609. (Pubitemid 37025572)
33. Goebeler, M., J. Roth, U. Henseleit, C. Sunderkotter, and C. Sorg. 1993. Expression and complex assembly of calcium-binding proteins MRP8 and MRP14 during differentiation of murine myelomonocytic cells. J. Leukocyte Biol. 53: 11-18. (Pubitemid 23048043)
34. Hunter, M. J., and W. J. Chazin. 1998. High level expression and dimer characterization of the S100 EF-hand proteins, migration inhibitory factor-related proteins 8 and 14. J. Biol. Chem. 273: 12427-12435.
35. Umemura, N., M. Saio, T. Suwa, Y. Kitoh, J. Bai, K. Nonaka, G. F. Ouyang, M. Okada, M. Balazs, R. Adany, et al. 2008. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J. Leukocyte Biol. 83: 1136-1144. (Pubitemid 351960345)
36. Serafini, P., I. Borrello, and V. Bronte. 2006. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 16: 53-65. (Pubitemid 43139709)
37. Rossner, S., C. Voigtlander, C. Wiethe, J. Hanig, C. Seifarth, and M. B. Lutz. 2005. Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro. Eur. J. Immunol. 35: 3533-3544. (Pubitemid 43025534)
38. Movahedi, K., M. Guilliams, J. Van den Bossche, R. Van den Bergh, C. Gysemans, A. Beschin, P. De Baetselier, and J. A. Van Ginderachter. 2008. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111: 4233-4244.
39. Sawanobori, Y., S. Ueha, M. Kurachi, T. Shimaoka, J. E. Talmadge, J. Abe, Y. Shono, M. Kitabatake, K. Kakimi, N. Mukaida, and K. Matsushima. 2008. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 1111: 5457-5466.
40. Seth, A., R. Kitching, G. Landberg, J. Xu, J. Zubovits, and A. M. Burger. 2003. Gene expression profiling of ductal carcinomas in situ and invasive breast tumors. Anticancer Res. 23: 2043-2051. (Pubitemid 36897163)
41. Carlsson, H., S. Petersson, and C. Enerback. 2005. Cluster analysis of S100 gene expression and genes correlating to psoriasin (S100A7) expression at different stages of breast cancer development. Int. J. Oncol. 27: 1473-1481.
42. Arai, K., S. Takano, T. Teratani, Y. Ito, T. Yamada, and R. Nozawa. 2008. S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. Curr. Cancer Drug Targets 8: 243-252. (Pubitemid 351881350)
43. Hobbs, J. A., R. May, K. Tanousis, E. McNeill, M. Mathies, C. Gebhardt, R. Henderson, M. J. Robinson, and N. Hogg. 2003. Myeloid cell function in MRP-14 (S100A9) null mice. Mol. Cell. Biol. 23: 2564-2576.
44. Manitz, M. P., B. Horst, S. Seeliger, A. Strey, B. V. Skryabin, M. Gunzer, W. Frings, F. Schonlau, J. Roth, C. Sorg, and W. Nacken. 2003. Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro. Mol. Cell. Biol. 23: 1034-1043.
45. Nacken, W., and C. Kerkhoff. 2007. The hetero-oligomeric complex of the S100A8/S100A9 protein is extremely protease resistant. FEBS Lett. 581: 5127-5130. (Pubitemid 47576097)
46. Arai, K., T. Teratani, R. Nozawa, and T. Yamada. 2001. Immunohistochemical investigation of S100A9 expression in pulmonary adenocarcinoma: S100A9 expression is associated with tumor differentiation. Oncol. Rep. 8: 591-596. (Pubitemid 33758460)
47. Shen, J., M. D. Person, J. Zhu, J. L. Abbruzzese, and D. Li. 2004. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res. 64: 9018-9026.
48. Cross, S. S., F. C. Hamdy, J. C. Deloulme, and I. Rehman. 2005. Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology 46: 256-269.
49. Hermani, A., J. Hess, B. De Servi, S. Medunjanin, R. Grobholz, L. Trojan, P. Angel, and D. Mayer. 2005. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin. Cancer Res. 11: 5146-5152. (Pubitemid 41003699)
50. Ryckman, C., K. Vandal, P. Rouleau, M. Talbot, and P. A. Tessier. 2003. Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J. Immunol. 170: 3233-3242. (Pubitemid 36302201)
51. Sinha, P., V. K. Clements, S. Miller, and S. Ostrand-Rosenberg. 2005. Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol. Immunother. 54: 1137-1142. (Pubitemid 41396817)
52. Sica, A., and V. Bronte. 2007. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117: 1155-1166. (Pubitemid 46718400)
53. Gabrilovich, D. I., V. Bronte, S. H. Chen, M. P. Colombo, A. Ochoa, S. Ostrand-Rosenberg, and H. Schreiber. 2007. The terminology issue for myeloid- derived suppressor cells. Cancer Res. 67: 425, author reply 426.
54. Gallina, G., L. Dolcetti, P. Serafini, C. De Santo, I. Marigo, M. P. Colombo, G. Basso, F. Brombacher, I. Borrello, P. Zanovello, et al. 2006. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest. 116: 2777-2790. (Pubitemid 44511641)
55. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66: 1123-1131.
56. + myeloid cells. Cancer Res. 66: 6807-6815.
57. Bronte, V., P. Serafini, C. De Santo, I. Marigo, V. Tosello, A. Mazzoni, D. M. Segal, C. Staib, M. Lowel, G. Sutter, et al. 2003. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J. Immunol. 170: 270-278. (Pubitemid 36026149)
58. + T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 172: 989-999.
59. Bronte, V., P. Serafini, A. Mazzoni, D. M. Segal, and P. Zanovello. 2003. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol. 24: 302-306. (Pubitemid 36694880)
60. Kusmartsev, S., and D. I. Gabrilovich. 2003. Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J. Leukocyte Biol. 74: 186-196. (Pubitemid 38040415)
61. Pan, P. Y., G. X. Wang, B. Yin, J. Ozao, T. Ku, C. M. Divino, and S. H. Chen. 2008. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 111: 219-228.
62. Ohm, J. E., D. I. Gabrilovich, G. D. Sempowski, E. Kisseleva, K. S. Parman, S. Nadaf, and D. P. Carbone. 2003. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 101: 4878-4886.
63. Diaz-Montero, C. M., M. L. Salem, M. I. Nishimura, E. Garrett-Mayer, D. J. Cole, and A. J. Montero. 2008. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. epub ahead of print.
64. Fuellen, G., D. Foell, W. Nacken, C. Sorg, and C. Kerkhoff. 2003. Absence of S100A12 in mouse: implications for RAGE-S100A12 interaction. Trends Immunol. 24: 622-624. (Pubitemid 37485909)
65. + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11: 6713-6721.